Clinical research of capecitabine monotherapy or in combination with oxaliplatin concurrent chemoradiotherapy on patients with advanced colorectal cancer
10.13699/j.cnki.1001-6821.2016.02.011
- VernacularTitle:卡培他滨单药或联合奥沙利铂同步放化疗对晚期直肠癌的临床疗效研究
- Author:
Xin-Cheng HUANG
1
;
Yu-Bin WANG
;
Chen-Guang XU
;
Xin-Guo YU
;
Guang YE
Author Information
1. 泰顺人民医院 外二科
- Keywords:
capecitabine;
oxaliplatin;
advanced colorectal cancer;
chemotherapy
- From:
The Chinese Journal of Clinical Pharmacology
2016;(2):129-131
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of capecitabine monotherapy or in combination with oxaliplatin concurrent chemoradio-therapy on patients with advanced colorectal cancer.Methods Fifty-two patients with advanced colorectal cancer were randomly divided into treatment group and control group , 26 cases in each group.Two groups were all taken 6 mV X -ray irradiation, 5 times a week, totally five weeks.On the same time , control group was given capecitabine , twice a day, with the total dose of 1500-1700 mg· m-2 .Treatment group was given oxaliplatin total dose of 50 -75 mg · m -2 , once a week , and capecitabine, twice a day, with the total dose of 1200-1550 mg· m-2.And 35 d a course , all patients were given three courses treatment.Clini-cal efficacy , improvement in quality of life and adverse drug reactions of the two groups were observed.Results After treatment, the objective response rate in treatment group (76.93%) was significantly higher than that in control group ( 42.31%, P<0.05 ); the quality of life in treat-ment group was significantly better than that in control group ( P<0.05 ).The incidence rate adverse reactions in treatment group were significantly lower than that in control group ( P<0.05 ).Conclusion Capecitabine combined with oxaliplatin for the treatment of patients with advanced colorectal cancer had a good clinical efficacy , low incidence of adversereactions , which can improve the quality of life.
